MCID: MLG064
MIFTS: 42

Malignant Ependymoma

Categories: Cancer diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Malignant Ependymoma

MalaCards integrated aliases for Malignant Ependymoma:

Name: Malignant Ependymoma 12 15
Ependymal Neoplasm 12 17
Ependymal Tumors 12 55
Experimental Organism Malignant Ependymoma 72
Anaplastic Ependymoma 72
Ependymoma of Brain 72
Ependymal Tumor 72

Classifications:



External Ids:

Disease Ontology 12 DOID:5074
NCIt 50 C6770
UMLS 72 C0238029 C0280788 C1333407 more

Summaries for Malignant Ependymoma

Disease Ontology : 12 A malignant glioma that is derived from ependymal cells, a type of glial cell, located in ventricle lining within the central part of the brain.

MalaCards based summary : Malignant Ependymoma, also known as ependymal neoplasm, is related to benign ependymoma and ependymoma, and has symptoms including seizures, vomiting and headache. An important gene associated with Malignant Ependymoma is NF2 (Neurofibromin 2), and among its related pathways/superpathways is Hippo signaling pathway - multiple species. The drugs Donepezil and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells, and related phenotypes are respiratory system and vision/eye

Related Diseases for Malignant Ependymoma

Diseases in the Ependymoma family:

Benign Ependymoma Malignant Ependymoma
Malignant Adult Ependymoma

Diseases related to Malignant Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Related Disease Score Top Affiliating Genes
1 benign ependymoma 31.3 NF2 GFAP
2 ependymoma 31.0 RELA NF2 GFAP
3 anaplastic ependymoma 30.3 RELA NF2 GFAP
4 neurilemmoma 30.3 NF2 GFAP
5 meningioma, radiation-induced 30.1 NF2 GFAP
6 glial tumor 11.6
7 spinal cord ependymoma 11.3
8 glioma susceptibility 1 11.3
9 subependymal glioma 11.3
10 brain ependymoma 11.3
11 cerebral convexity meningioma 10.5 NF2 GFAP
12 intraventricular meningioma 10.4 NF2 GFAP
13 rhabdoid meningioma 10.4 NF2 GFAP
14 cornea cancer 10.4 NF2 GFAP
15 spinal cancer 10.4 NF2 GFAP
16 cellular ependymoma 10.4 RELA GFAP
17 plexiform schwannoma 10.4 NF2 GFAP
18 chordoid glioma 10.4 NF2 GFAP
19 atypical neurofibroma 10.4 NF2 GFAP
20 neurilemmoma of the fifth cranial nerve 10.3 NF2 GFAP
21 trigeminal nerve neoplasm 10.3 NF2 GFAP
22 tanycytic ependymoma 10.3 NF2 GFAP
23 cerebellopontine angle tumor 10.2 NF2 GFAP
24 astrocytoma 10.1
25 subependymoma 10.1
26 neuroma 10.1 NF2 GFAP
27 medulloblastoma 10.0
28 papilloma of choroid plexus 10.0
29 squamous cell papilloma 10.0
30 papilloma 10.0
31 oligodendroglioma 10.0
32 medulloepithelioma 10.0
33 clear cell ependymoma 10.0
34 glioma 10.0
35 angiocentric glioma 10.0
36 rare surgical neurologic disease 10.0
37 meningioma, familial 9.9
38 spinal meningioma 9.9
39 glioblastoma multiforme 9.9
40 secretory meningioma 9.9
41 lymphoplasmacyte-rich meningioma 9.9
42 myxopapillary ependymoma 9.9
43 glioblastoma 9.9
44 pilocytic astrocytoma 9.9
45 rapidly involuting congenital hemangioma 9.9
46 neurofibromatosis, type iv, of riccardi 9.9
47 neural tube defects 9.9
48 chordoma 9.9
49 neuroblastoma 1 9.9
50 schinzel-giedion midface retraction syndrome 9.9

Graphical network of the top 20 diseases related to Malignant Ependymoma:



Diseases related to Malignant Ependymoma

Symptoms & Phenotypes for Malignant Ependymoma

UMLS symptoms related to Malignant Ependymoma:


seizures, vomiting, headache, nausea

MGI Mouse Phenotypes related to Malignant Ependymoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 respiratory system MP:0005388 9.35 CD207 LOXL3 NF2 RELA YAP1
2 vision/eye MP:0005391 9.1 ARVCF GFAP LOXL3 MIB2 NF2 RELA

Drugs & Therapeutics for Malignant Ependymoma

Drugs for Malignant Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 3 120014-06-4 3152
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
3
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
4
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
5 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
6 Analgesics Phase 3
7 Central Nervous System Depressants Phase 3
8 Nootropic Agents Phase 3
9 Peripheral Nervous System Agents Phase 3
10 Cholinesterase Inhibitors Phase 3
11 Cholinergic Agents Phase 3
12 Liver Extracts Phase 3
13 Cola Phase 3
14 Anesthetics, Intravenous Phase 3
15 Narcotics Phase 3
16 Analgesics, Opioid Phase 3
17 Adjuvants, Anesthesia Phase 3
18 Anesthetics, General Phase 3
19 Anesthetics Phase 3
20 Dopamine Agents Phase 3
21 Neurotransmitter Agents Phase 3
22 Central Nervous System Stimulants Phase 3
23 Dexmethylphenidate Hydrochloride Phase 3
24 Neurotransmitter Uptake Inhibitors Phase 3
25 Dopamine Uptake Inhibitors Phase 3
26
Ethanol Approved Phase 1, Phase 2 64-17-5 702
27
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
28
Etoposide Approved Phase 2 33419-42-0 36462
29
Pregabalin Approved, Illicit, Investigational Phase 2 148553-50-8 5486971
30
Levetiracetam Approved, Investigational Phase 2 102767-28-2 441341
31
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
32
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
33
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
34
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
35
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
36
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
37
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
38
leucovorin Approved Phase 2 58-05-9 143 6006
39
Tamoxifen Approved Phase 2 10540-29-1 2733526
40
Sodium citrate Approved, Investigational Phase 2 68-04-2
41
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
42
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60700
43
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616 46835353
44
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
45
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
46
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
47
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
48
Procarbazine Approved, Investigational Phase 2 671-16-9 4915
49
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
50
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
2 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
4 Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
5 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
6 A Phase II Trial of Poly ICLC in Patients With Recurrent Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
7 A PHASE II TRIAL OF ETOPOSIDE AND CISPLATIN IN THE TREATMENT OF RECURRENT EPENDYMOMAS Completed NCT00002876 Phase 2 cisplatin;etoposide
8 A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
9 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
10 Improved Characterization of Brain Tumors By MRI and MRS Completed NCT00274755 Phase 2 chemotherapy
11 A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
12 PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS Completed NCT00002752 Phase 1, Phase 2
13 A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue Completed NCT01032200 Phase 2 Armodafinil
14 Dynamic Contrast-Enhanced Magnetic Resonance Imaging With Bevacizumab in Combination With Irinotecan for Malignant Gliomas Completed NCT00352521 Phase 2 bevacizumab;irinotecan
15 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
16 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
17 Phase I Study of Intra-Tumoral, Radiolabeled, Anti-Tenascin Monoclonal Antibody 81C6 in the Treatment of Patients With Malignant Primary Brain Tumors Completed NCT00003478 Phase 1, Phase 2
18 Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases Completed NCT00070161 Phase 2 donepezil hydrochloride
19 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
20 A Pilot Study of Tamoxifen, Carboplatin and Topotecan in the Treatment of Recurrent or Refractory Primary Brain or Spinal Cord Tumors or Metastatic Epithelial Cancers With Central Nervous System Metastases Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
21 Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
22 Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
23 A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma Completed NCT00826241 Phase 2 Temozolomide;Lapatinib
24 A Randomized Phase I/II Study of ABT-888 in Combination With Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma Completed NCT01026493 Phase 1, Phase 2 temozolomide 60 mg x 21 days;temozolomide 75 mg x 21 days;ABT-888 20 mg x 21 days;ABT-888 40 mg x 21 days;Temozolomide 150 mg x 5 days;ABT-888 40 mg x 5 days
25 Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma Completed NCT02155920 Phase 2 Everolimus
26 Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial Recruiting NCT01295944 Phase 2 Carboplatin;Bevacizumab
27 Phase II Clinical Trial of Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma Recruiting NCT03727841 Phase 2 Marizomib
28 Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms Active, not recruiting NCT00445965 Phase 2
29 Phase II Trial of Ritonavir/Lopinavir in Patients With Progressive of Recurrent High-Grade Gliomas Terminated NCT01095094 Phase 2 ritonavir;lopinavir
30 Phase II Study of Antineoplastons A10 and AS2-1 Infusions in Patients With Ependymoma Terminated NCT00003479 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
31 Defining Functional Tissue in Brain Tumors With Integrated Neuroimaging (Pilot Study) Withdrawn NCT00005083 Phase 2
32 Phase I Study of Enzastaurin and Temozolomide in Patients With Gliomas Unknown status NCT00516607 Phase 1 enzastaurin hydrochloride;temozolomide
33 Phase I Study Of SCH66336 (Lonafarnib), A Farnesyl Protein Transferase Inhibitor In Combination With Temozolomide In Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
34 Photodynamic Therapy For Childhood Brain Tumors, A Phase I Study Unknown status NCT00002647 Phase 1 verteporfin
35 Determination of the In-Tumor-Concentration of Imatinib Mesylate in Malignant Glioma After Oral Administration Completed NCT00401024 Phase 1 imatinib mesylate
36 PHASE I, OPEN LABEL, MULTICENTER DOSE ESCALATION STUDY OF GLIADEL IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA Completed NCT00004028 Phase 1 carmustine
37 PROTOCOL FOR A PHASE I STUDY OF INTRACYSTIC ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 IN THE TREATMENT OF PATIENTS WITH RECURRENT CYSTIC GLIOMAS Completed NCT00002753 Phase 1
38 A Phase I Trial Of A Thalidomide Analog, CC-5013, For The Treatment Of Patients With Recurrent High-Grade Gliomas Completed NCT00036894 Phase 1 lenalidomide
39 A Phase I Study of Extended Low Dose Temozolomide (SCH 52365, Temodar (R)) and Carmustine (BCNU) in the Treatment of Malignant Gliomas After Radiation Therapy Completed NCT00005637 Phase 1 carmustine;temozolomide
40 A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment Completed NCT01480050 Phase 1 temozolomide;Mibefradil
41 Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 Completed NCT01082926 Phase 1
42 A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF Completed NCT00069940 Phase 1
43 Phase I Study of Intrathecal 131-I-3F8 Monoclonal Antibody in Patients With GD2 Positive Leptomeningeal Neoplasms Completed NCT00003022 Phase 1
44 Phase I Dose Escalation of Gleevec in Combination With PTK787/ZK 222584 (PTK/ZK) Plus Hydroxyurea Completed NCT00387933 Phase 1 hydroxyurea;imatinib mesylate;vatalanib
45 Pilot Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Genetically-Modified Autologous CD8+ T Cell Clones Completed NCT00730613 Phase 1
46 A Pilot Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
47 A Phase I Trial of Subcutaneous And/Or Oral Calcitriol [(1,25-COH)2D3] and Carboplatin in Advanced Solid Tumors Completed NCT00008086 Phase 1 carboplatin
48 A Phase I Study of Bortezomib and Temozolomide in Patients With Refractory Solid Tumors Completed NCT00544284 Phase 1 bortezomib;temozolomide
49 Phase I Evaluation of Sodium Stibogluconate in Combination With Interferon α-2b Followed by Cisplatin, Vinblastine and Dacarbazine for Patients With Melanoma or Malignancies Potentially Responsive to SSG and/or Interferons Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine
50 A PHASE I STUDY OF THE COMBINATION OF CAI AND PACLITAXEL IN ADULT PATIENTS WITH REFRACTORY CANCERS OR LYMPHOMA Completed NCT00019019 Phase 1 carboxyamidotriazole;paclitaxel

Search NIH Clinical Center for Malignant Ependymoma

Genetic Tests for Malignant Ependymoma

Anatomical Context for Malignant Ependymoma

MalaCards organs/tissues related to Malignant Ependymoma:

41
Brain, Spinal Cord, T Cells, Bone, Liver, Pineal, Bone Marrow

The Foundational Model of Anatomy Ontology organs/tissues related to Malignant Ependymoma:

19
Ventricle Lining

Publications for Malignant Ependymoma

Articles related to Malignant Ependymoma:

(show top 50) (show all 180)
# Title Authors PMID Year
1
Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. 9 38
10433955 1999
2
Expression of glial fibrillary acidic protein, vimentin, fibronectin, and N-myc oncoprotein in primary human brain tumor cell explants. 9 38
1668298 1991
3
MYCN amplification drives an aggressive form of spinal ependymoma. 38
31414211 2019
4
Detecting the long non‑coding RNA signature related to spinal cord ependymal tumor subtype using a genome‑wide methylome analysis approach. 38
31257484 2019
5
Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China. 38
31324163 2019
6
Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. 38
30325077 2019
7
Trends in International Incidence of Pediatric Cancers in Children Under 5 Years of Age: 1988-2012. 38
30984908 2019
8
Subpial Cervical Subependymoma: Report of an Unusual Tumor with Review of Literature. 38
30937068 2019
9
Can apparent diffusion coefficient values help distinguish between different types of pediatric brain tumors? 38
30627595 2019
10
Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. 38
30514397 2018
11
DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. 38
30053291 2018
12
Survivorship in adults with malignant brain and other central nervous system tumor from 2000-2014. 38
29850889 2018
13
Advantages of high b-value diffusion-weighted imaging for preoperative differential diagnosis between embryonal and ependymal tumors at 3 T MRI. 38
29571787 2018
14
Prognostic Implications of Histological Clear Cells in High-Grade Intracranial Ependymal Tumors: A Retrospective Analysis from a Tertiary Care Hospital in Pakistan. 38
29682026 2018
15
Neoplastic Myelopathies. 38
29613896 2018
16
Survival of Ventricular and Periventricular High-Grade Gliomas: A Surveillance, Epidemiology, and End Results Program-Based Study. 38
29258929 2018
17
EANO guidelines for the diagnosis and treatment of ependymal tumors. 38
29194500 2018
18
Unedited microneurosurgery of a pineal region ependymoma. 38
30687571 2018
19
Recent Advances in the Classification and Treatment of Ependymomas. 38
28795287 2017
20
Lymph node metastasis of presacral ependymoblastoma in a young child. 38
28215462 2017
21
Pediatric Ependymoma: A Proteomics Perspective. 38
28387652 2017
22
Recent advances in subtyping tumors of the central nervous system using molecular data. 38
27893285 2017
23
Genetic differences on intracranial versus spinal cord ependymal tumors: a meta-analysis of genetic researches. 38
27637901 2016
24
Novel fusion genes and chimeric transcripts in ependymal tumors. 38
27401149 2016
25
Primary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases. 38
26990854 2016
26
Spectrum of primary intracranial tumors at a tertiary care neurological institute: A hospital-based brain tumor registry. 38
27147159 2016
27
Chemotherapy for intracranial ependymoma in adults. 38
27108407 2016
28
Prognostic factors in ependymal tumors: Molecular biology trumps histopathology. 38
26954808 2016
29
Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. 38
26113311 2016
30
Histologic classification of gliomas. 38
26948349 2016
31
SOX10 and Olig2 as negative markers for the diagnosis of ependymomas: An immunohistochemical study of 98 glial tumors. 38
26287936 2016
32
Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma. 38
27390862 2016
33
Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: a new brain tumor entity? 38
25795305 2015
34
Cytoplasmic 5-Lipoxygenase Staining Is a Highly Sensitive Marker of Human Tumors of the Choroid Plexus. 38
26185315 2015
35
Role of Evaluating MGMT Status and 1p36 Deletion in Radiosurgery-Induced Anaplastic Ependymoma That Rapidly and Completely Resolved by Temozolomide Alone: Case Report and Review of the Literature. 38
26251808 2015
36
Establishment and maintenance of a standardized glioma tissue bank: Huashan experience. 38
24929994 2015
37
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. 38
25965575 2015
38
NHERF1/EBP50 is an organizer of polarity structures and a diagnostic marker in ependymoma. 38
25775275 2015
39
Ependymal tumors with oligodendroglioma like clear cells: Experience from a tertiary care hospital in Pakistan. 38
26664928 2015
40
Characteristics of childhood glial tumors, management approaches and life expectancy of the patients. 38
25261659 2014
41
Population-based survival analyses of central nervous system tumors from 1994 to 2008. An up-dated study in the temozolomide-era. 38
24794586 2014
42
Prognostic relevance of global histone 3 lysine 9 acetylation in ependymal tumors. 38
24116725 2013
43
[Occurrence and molecular pathology of low grade gliomas]. 38
24358685 2013
44
Epidemiology of pediatric primary malignant central nervous system tumors in Iran: a 10 year report of National Cancer Registry. 38
23562043 2013
45
Ventricular and extraventricular ependymal tumors in 18 cats. 38
22798290 2013
46
Supratentorial ependymomas in children: Analysis of nine cases. 38
23772237 2013
47
Adult-onset angiocentric glioma of epithelioid cell-predominant type of the mesial temporal lobe suggestive of a rare but distinct clinicopathological subset within a spectrum of angiocentric cortical ependymal tumors. 38
22151480 2012
48
Correlation of expression pattern of aquaporin-1 in primary central nervous system tumors with tumor type, grade, proliferation, microvessel density, contrast-enhancement and perilesional edema. 38
23361277 2012
49
Identification of t(1;19)(q12;p13) and ploidy changes in an ependymosarcoma: a cytogenetic evaluation. 38
22551918 2012
50
Claudin-6 is a nonspecific marker for malignant rhabdoid and other pediatric tumors. 38
21989342 2012

Variations for Malignant Ependymoma

Expression for Malignant Ependymoma

Search GEO for disease gene expression data for Malignant Ependymoma.

Pathways for Malignant Ependymoma

Pathways related to Malignant Ependymoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.09 YAP1 NF2

GO Terms for Malignant Ependymoma

Biological processes related to Malignant Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of neurogenesis GO:0050767 9.26 YAP1 NF2
2 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.16 YAP1 RELA
3 response to progesterone GO:0032570 8.96 YAP1 RELA
4 regulation of stem cell proliferation GO:0072091 8.62 YAP1 NF2

Molecular functions related to Malignant Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 structural molecule activity GO:0005198 9.13 LAMA2 KRT75 GFAP
2 activating transcription factor binding GO:0033613 8.62 YAP1 RELA

Sources for Malignant Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....